Companies: 10,795·Total market cap: $144.5T

Isracann Biosciences Inc.

Isracann Biosciences Inc.

ISCNFOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$1760

P/E Ratio—

52W High$0.0001

52W Low$0.00001

Avg Volume43K

Open$0.00

Beta0.19

Net Income Financials Revenue

Isracann Biosciences Inc. (ISCNF) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

ISCNF · net income · updated Jun 9, 2026

Core profitability metrics

ISCNF · net income · margin · TTM · CAGR

Net income was −$4.7M for FY2022 (fiscal year ending 2022-05-31), up 81.3% year-over-year. Net profit margin was —.

FY2022 Net Income−$4.7M▲ +81.3% YoY

Trailing 12M (TTM)−$4.5Mtrailing 4 quarters sum

Net Profit Margin——

YoY Change+81.3%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · ISCNF net income history · ISCNF profit margin

Annual net income data

ISCNF · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2022Loss−$4.7M▲ +81.3%—$0

FY2021Loss−$25.2M▼ 3.9%—$0

FY2020Loss−$24.2M▼ 152.2%—$0

FY2019Loss−$9.6M▼ 28.4%—$0

FY2018Loss−$7.5M▼ 1018.6%-636.9%$1.2M

Net income vs peers (Healthcare)

ISCNF vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Isracann Biosciences Inc.YOU

ISCNF

−$4.7M+81.3%—

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Isracann Biosciences Inc. (ISCNF) reported net income of −$4.7M for FY2022 (fiscal year ending 2022-05-31), up 81.3% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Isracann Biosciences Inc. has not yet achieved annual profitability based on available data (12 fiscal years). The company has reported net losses across all available periods.

Isracann Biosciences Inc.'s net profit margin was — for FY2022, based on the latest annual results.

Investors sometimes search for "Isracann Biosciences Inc. net worth" — the company's market capitalization is a separate figure from ISCNF net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

ISCNF net income · 4 questions

Isracann Biosciences Inc. is not currently profitable on an annual basis. The company reported a net loss of $4.7M for FY2022.

is ISCNF profitabledoes ISCNF make a profitISCNF profitabilityISCNF profitable company

▸ Source: FMP /income-statement · GAAP · Isracann Biosciences Inc. · Isracann Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026